The company founded in 2014, is a French-based SME, developing and designing microfluidic devices and Nerve-on-Chip: NOC (reconstructed neuron networks at the micron scale).
They offer new approaches for evaluation and screening of molecules (compartmentalized pharmacology, functional networks). Applications of the technology cover Alzheimer Disease, Parkinson Disease, Toxicology and Neuro-Electronic interfaces.
Nerves-on-chip are more accurate than conventional cellular cultures. They standardize the parameters of neuronal dialogue, avoid animal testing, help prioritization of Lead candidates and can provide personalized medicine.
2. General figures:
Target market of NOC: $3.5 billion.
The company is looking for investors to develop R&D projects in Singapore.